COVID-19 and Vaccination Impact on Liver Injury Detection During Clinical Trials

Research conducted by Genentech Inc.'s IQ DILI Initiative highlights the need for guidance in evaluating liver tests due to COVID-19, its treatments, and vaccination. The study emphasizes the variability of liver-related manifestations in non-hospitalized patients and the potential for liver injury to occur even after symptoms resolve. The researchers propose recommendations for clinical trials to address this gap, including considering COVID-19 testing as part of drug-induced liver injury (DILI) causality assessment.

Key Takeaways:

• The COVID-19 pandemic has lasting implications for clinical trials, particularly in evaluating liver tests due to the virus, its treatments, and vaccination.
• Liver-related manifestations in non-hospitalized patients with COVID-19 can be highly varied and may occur even after symptoms resolve and testing is negative.
• Treatments for COVID-19 may cause liver injury or alter pharmacokinetics, and COVID-19 vaccination has been associated with rare but clear hepatotoxicity.
• The researchers propose that clinical trial participants should be asked about their receipt of COVID-19 vaccination when liver tests are abnormal during screening and as part of DILI causality assessment.
• COVID-19 testing should be considered part of DILI causality assessment to prevent premature termination of the investigational drug.
• The IQ DILI Initiative recommends a consensus approach to address the gap in guidance for evaluation of elevated liver tests due to COVID-19.
• Additional information can be obtained by contacting Ajit Dash at Genentech Inc. or by referencing the publication in Drug Safety.

Statistics:

• The study found that liver injury may occur after COVID-19 symptoms resolve and testing is negative.
• COVID-19 vaccination has been associated with rare but clear hepatotoxicity, typically consistent with drug-induced autoimmune-like hepatitis.
• Liver injury occurred with mRNA and viral vector vaccines, and in individuals with and without underlying autoimmune or liver diseases.

Sources:

• The Impact of Covid-19 and Covid-19 Vaccination On Detection, Assessment, and Management of Suspected Acute Drug-induced Liver Injury Occurring During Clinical Trials: Consensus Recommendations From the Iq Dili Initiative. Drug Safety, 2025.
• Adis Int Ltd, 5 The Warehouse Way, Northcote 0627, Auckland, New Zealand.
• Ajit Dash, Genentech Inc., Early Dev Safety, South San Francisco, CA 94080, United States.
• Melissa Palmer, Daniel Seekins, Mark Avigan, John Marcinak, Don C. Rockey, Arie Regev, Vineet K. Shastri and James H. Lewis.